Prognostic importance of antigen-presenting dendritic cells during vaccine therapy in a murine hepatitis B virus carrier

Immunology

Volumn 96, Issue 1, 1999, Pages 98-108

  Akbar, F ^a   Horhke, N ^a   Onji, M ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HEPATITIS B VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HEPATITIS B; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VACCINATION; VIRUS HEPATITIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOLOGICAL MARKERS; DENDRITIC CELLS; DNA, VIRAL; HEMOCYANIN; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOTHERAPY, ACTIVE; IN SITU HYBRIDIZATION; LIVER; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; PROGNOSIS; STATISTICS, NONPARAMETRIC;

EID: 0032891984     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1999.00668.x     Document Type: Article

References (28)

1. 1. DUSHEIKO G. & HOOFNAGLE J.H. (1991) Hepatitis B. Oxford Textbook of Clinical Hepatology, p. 571. Oxford University Press, New York.
2. 2. PETERS M., VIERLING J., GRENSHWIN M.E., MILLICH D., CHISARI F.V. & HOOFNAGLE J.H. (1991) Immunology and the liver. Hepatology 13, 977.
3. 3. THOMAS H.C. (1991). Pathogenesis of chronic HBV infection and mechanisms of action of anti viral compounds. In: Viral Hepatitis and Liver Disease (eds HOLLINGER F.B., LEMON S. & MAGOLIS H.S.), p. 612. Williams & Wilkins, Baltimore.
4. 4. PERIOLLO R.P. (1991). Treatment of chronic hepatitis B. In: Viral Hepatitis and Liver Disease (eds HOLLINGER F.B., LEMON S. & MAGOLIS H.S.), p. 616. Williams & Wilkins, Baltimore.
5. 5. PERIOLLO R.P. (1993). Interferon in the management of chronic hepatitis B. Dig Dis Sci 38, 577.
6. 6. POL S. (1995) Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmather 49, 105.
7. 7. POL S., DRISS F., MICHEL M., NALPES B., BERTHELOT P. & BRECHOT C. (1994) Specific vaccine therapy in chronic hepatitis B infection. Lancet 344, 342.
8. 8 WEN Y.-M., WU X.-H., HU D.-C., ZHANG Q.-P. & GUO S.-Q. (1995) Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345, 1575.
9. 9. ARAKI K., MIYAZAKI J., HINO O. et al. (1989) Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Aca, Sci, USA 86, 207.
10. 10. CHISARI F.V. (1995). Hepatitis B virus transgenic mice: insights into the virus and disease. Hepatology 22, 1316.
11. 11. GUILHOT S., GUIDOTM L.G. & CHISARI F.V. (1993) Interleukin-2 down regulates hepatitis B virus gene expression in transgenic mice by a post transcriptional mechanism. J Virol 67, 7444.
12. 12. AKBAR S.M.F., KAJINO K., TANIMOTO T. et al. (1997) Placebo-controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. J Hepatol 26, 131.
13. 13. AKBAR S.M.F., ONJI M., INABA K., YAMAMURA K. & OHTA Y. (1993) Low responsiveness of hepatitis B virus-transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen-presenting activity of dendritic cell. Immunology 78, 468.
14. 14. AKBAR S.M.F., INABA K. & ONJI M. (1996) Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice: abrogation of immune response defect to a T-cell-dependent antigen. Immunology 87, 519.
15. 15. METLAY J.P., WITMER-PACK M.D., AGGER R., CROWLF.Y M.T., LAWLESS D. & STEINMAN R.M. (1990) The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J Exp.Med 171, 1753.
16. 16. CROWLEY M., INABA K., WITMET-PACK M. & STEINMAN R.M. (1989) The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. Cell Immunol 118, 108.
17. 17. INABA K., METLAY J.P., CROWLEY M.T. & STEINMAN R.M. (1990) Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp MeD 172, 631.
18. 18. GRABBE S., BEISSERT S., SCHWARZ T. & GRANSTEIN R.D. (1995) Dendritic cells as initiators of tumor immune response; a possible strategy for immunotherapy? Immunol Today 16, 117.
19. 19. GABRILOVICH D.I., NADAF S., CORAK J., BERZOFSKY J.A. & CARBONE D.P. (1996) Dendritic cells in antitumor immune responses. Cell Immunol 170, 111.
20. 20. LYNCH D.H., ANDREASEN A., MARASKOVSKY E., WHITMORE J., MILLER R.E. & SCHOH J.C.L. (1997) Ft13 ligand induces tumor regression and antitumor immune response in vivo. Nat Med 3, 625.
21. 21. HSU F.J., BENIKE C., FAGNONI F. et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2, 52.
22. 22. CELLUZZI C.M. & FALO L.D. JR (1998) Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 160, 3081.
23. 23. VITIELLO A., ISHIOKA G., GREY H.M. et al. (1995) Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection.1. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95, 341.
24. 24. WEN Y.-M., XIONG S.-D. & ZHANG W. (1994) Solid matrixantibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection. J Gen Virol 75, 335.
25. 25. KUROSE K., AKBAR S.M.F., YAMAMOTO K. & ONJI M. (1997) Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells. Immunology 92, 494.
26. 26. MATZINGER P. (1994) Tolerance, danger and extended family. Annu Rev Immunol 12, 991.
27. 27. RIDGE J.P., FUCHS E.J. & MATZINGER P. (1996) Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 271, 1723.
28. 28. MILICH D.R. & OHSARI F.V. (1982) Genetic refulation of the immune response to hepatitis B surface antigen (HBsAg). 1. H-2 restriction of the murine humoral immune response to the a and d determinants of HBsAg. J Immunol 129, 320.